Loading
Orchestra BioMed Holdings, Inc. Stock: price and insider trades · United States
US·Mcap US$327.6M
2 insiders bought €50k of shares over the last 90 days, the latest filed 08 Sept 2026.
Orchestra BioMed Holdings, Inc.: what insiders have been doing
Orchestra BioMed Holdings, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Orchestra BioMed Holdings, Inc. logged 42 filings by 11 insiders.
Purchases and sales both appear in the filings: 4 purchases (2 insiders, €105k) and 3 sales (2 insiders, €137k). Taken together, the sales exceed the purchases by €32k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Sherman Darren filed the largest sale, €84k, on 2 October 2026, which represents 0.026% of the company's market value.
In the case of 1 purchase, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 8 September 2026, 40 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (5,458 companies, median 22 filings), a count of 42 filings is above the norm. The full history, which starts in 2022, counts 23 purchases against 7 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 33.5 m USD and net income at -52.7 m USD.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
143
Thresholds
n/a
Buy Volume
€2M
23 ops. · all time
Sell Volume
€226,026
7 ops. · all time
Who traded when
BuySaleDavid P. Hochman7 buys
Darren Sherman2 buys2 sales
RTW Investments, LP2 buys1 sale
Andrew Lawrence Taylor2 buys
Eric S. Fain1 buy1 sale
Aryeh Jason1 buy
+1 other insider
Since the insiders bought
- +0.0%Entry US$5.45 · Close 16 Oct 2026 US$5.45
- +8.1%Entry US$5.04 · Close 16 Oct 2026 US$5.45
- +122.4%Entry US$2.45 · Close 16 Oct 2026 US$5.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Orchestra BioMed Holdings, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$12.43.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.45
Analyst consensus
7 analystsStrong buy
US$9.00Target US$12.43(+128%)US$20.00
Income statement
RevenueUS$33.5M
Gross profitUS$33.3M99% margin
EBITDA-US$51.2M-153% margin
Net income-US$52.7M-184.6% margin
Valuation
PER (forward)-3.6x
P/Book17.0x
Beta0.52
Balance sheet & cash
Market capUS$327.6M
Total debtUS$16M
Free Cash Flow-US$49.5M
Debt / Equity241%
Profitability & ownership
ROE-397.3%
ROA-45.7%
% insiders24.4%
% institutions47.8%
Last declaration on 2 October 2026
Declarations143 total
15,000 shares@ US$6.360.026% mcap7.2% of flowCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-26-113320:0
15,000 shares@ US$6.270.025% mcap7.7% of flowCommonSEC144:0001959173-26-007169
3,283 shares@ US$5.810.0052% mcap1.6% of flowCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-26-107143:0
10,000 shares@ US$4.790.013% mcap3.9% of flowCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-26-105690:0
Canonical exit: 2 Dec 2026 (T+90)
203 shares@ US$5.260.0003% mcap17.2% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-26-103205:0
4,925 shares@ US$5.260.0071% mcap2.2% of flowCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-26-103209:0
2,000 shares@ US$5.330.0029% mcap0.9% of flowCommon StockSEC:0001104659-26-103209:1
Canonical exit: 24 Nov 2026 (T+90)
3,076 shares@ US$5.260.0044% mcap3.9% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-26-103210:0
4,238 shares@ US$4.420.0052% mcap88.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-26-097174:0
4,885 shares@ US$4.420.0060% mcap100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-26-097183:0
3,761 shares@ US$4.420.0046% mcap100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-26-097195:0
5,145 shares@ US$4.420.0063% mcap37.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-26-097192:0
15,000 shares@ US$4.090.017% mcap5.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-26-090449:0
15,000 shares@ US$4.08610.017% mcap5.3% of flowCommonSEC144:0001959173-26-005567
15,000 shares@ US$4.320.018% mcap5.7% of flowCommonSEC144:0001959173-26-005000
17,327 sharesCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-26-077778:0
3,784 sharesCommon StockSEC:0001104659-26-077778:1
3,510 sharesCommon Stock, par value $0.0001 per shareSEC:0001104659-26-077777:0
17,327 sharesCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-26-077775:0
17,327 sharesCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-26-077780:0
4,261 sharesCommon StockSEC:0001104659-26-077780:1
34,653 sharesCommon Stock, par value $0.0001 per share ("Common Stock")SEC:0001104659-26-077767:0
3,510 sharesCommon StockSEC:0001104659-26-077767:1
1,250,032 shares0.0000% mcap0.0% of flowCommon StockSEC:0001231919-26-000427:0
32 shares@ US$4.130.0000% mcap0.0% of flowCommon StockSEC:0001231919-26-000427:1
25 of 143 declarations
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. is a company focused on developing innovative medical solutions. It specializes in creating medical devices for the treatment of cardiovascular diseases and other chronic conditions.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
